Teva U.S. sales plummet, Copaxone sets record

Generics giant Teva Pharmaceutical Industries ($TEVA) suffered another decline in U.S. sales, dampening third-quarter results. The Israeli company saw net income drop by 12.8% to $916 million, with U.S. revenues dropping by a whopping 48% to $845 million, compared with a period last year marked by several new product launches. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.